Publication date: Apr 14, 2025
Phosphoglycerate kinase 1 (PGK1) is a highly conserved enzyme that catalyzes the initial ATP-producing step in glycolysis. Improving cellular energy production by increasing PGK1 activity may be beneficial in multiple neurological conditions where cell metabolism is dysregulated, including Parkinson’s disease (PD) and motor neuron disease (MND). This review examines recent evidence that suggests increasing PGK1 activity may be beneficial in multiple neurological conditions and discusses the current challenges surrounding the development of PGK1-focused therapies. PGK1 has considerable therapeutic potential, but novel PGK1 activators are needed to maximize the benefit for patients.
| Concepts | Keywords |
|---|---|
| Atp | amyotrophic lateral sclerosis |
| Disease | neurodegeneration |
| Increasing | spinal muscular atrophy |
| Kinase | terazosin |
| Parkinson | therapy development |
Semantics
| Type | Source | Name |
|---|---|---|
| drug | DRUGBANK | ATP |
| pathway | REACTOME | Glycolysis |
| pathway | REACTOME | Metabolism |
| disease | MESH | Parkinson’s disease |
| disease | MESH | motor neuron disease |
| disease | MESH | amyotrophic lateral sclerosis |
| pathway | KEGG | Amyotrophic lateral sclerosis |
| disease | MESH | spinal muscular atrophy |
| drug | DRUGBANK | Terazosin |
Original Article
(Visited 2 times, 1 visits today)